Science jobs from Polyclone Bioservices Pvt. Ltd.

Science jobs from Polyclone Bioservices Pvt. Ltd.

Location:Bangalore(India)

Designation: Scientist (Bioinformatics)
Qualifications: M.Sc/ PhD
Experience: 0 – 1 yrs

Requirements:

• Candidates will have strong knowledge using–and coding functionality that
interacts with–public nucleotide and protein sequence databases, sequence
alignment software, and related computational genomic resources.

• Strong background in sequence analysis, genome annotation, analysis of
gene or protein expression, protein structure or docking prediction,
comparative genomics is a must. A broad knowledge of statistics and
statistical methods used in analyzing genomics data is preferred.

Desirable:

• C# under the .Net Framework as well as Perl.
• Knowledge of the R\Bioconductor programming language
• Strong background in multi-univariate and Bayesian statistics, and some
experience in machine-learning techniques (SVM, NN).
• We welcome expertise in Python, Bioperl, Ruby, Java, C++/C, and Matlab
• Understanding of scientific workflows, laboratory instrument interactions
and scientific data
• Ability to discuss informatics software specifically, bioinformatics,
chemo informatics,LIMS, SDMS, other Life Science analytical applications, at
varying levels of detail
• Ability to gather market / prospect requirements and scientific use cases
and contribute to effective implementation of scientific use cases in
complex data environments
• Writing research papers, posters, participation in conferences seminars

Website:http://www.polyclonebio.com

Note: Application expires on 28th April,2010

BioMicro Sells Microarray Assets to Roche

Roche Diagnostics said today that it has struck a deal with Salt Lake City-based BioMicro Systems to buy all of the products associated with the Roche NimbleGen microarray workflow.

These assets include instruments that are key to the Roche NimbleGen microarray workflow, such as the 4-and-12-bay NimbleGen Hybridization Systems.

Roche said that it will transfer the manufacturing capabilities associated with these products to its own in-house facility.

"Acquiring these assets will allow Roche complete control over the production, support, and service of these products to ensure continued timely distribution, full support, and the high level of service our customers have grown to expect from Roche," Roche NimbleGen VP of Marketing Andreas Görtz said in a statement.

NimbleGen originally partnered with BioMicro for custom hybridization for its chips in 2007, before it was acquired by Roche later that year.

Financial terms of the agreement were not released.

Merck KGaA to Buy Millipore for $7.2B

Merck KGaA has entered into a definitive agreement to acquire Millipore for $7.2 million in a cash deal that would create a life science research products giant with around $2.9 billion in annual revenues.

The firms announced the deal yesterday — several days after reports that Thermo Fisher Scientific had made a $6 billion bid for Millipore.

Under terms of the deal, Darmstadt, Germany's Merck will pay $107 per share for all of Millipore's stock for a total transaction value of roughly $7.2 billion. The deal values Millipore at 4.4 times its 2009 sales of $1.65 billion.

"By combining Millipore's bioscience and bioprocess knowledge with our own expertise in serving pharma customers, we will be able to unlock value in our chemicals business and transform it into a strong growth driver for Merck," Karl-Ludwig Kley, chairman of the executive board of Merck KGaA. "Through this acquisition, we will expand the overall product offering of the Merck Group, using the well-recognized Millipore brand in addition to our own brand."

Merck said that its chemicals business currently generates around 25 percent of its total revenues, but following the acquisition that will increase to 35 percent of total group revenues. Merck, which also has a large pharmaceuticals business, expects the combined business will generate annual cost synergies of around $100 million within three years of the closing of the deal.

Millipore's headquarters will remain in Billerica, Mass., the firms said, and will be combined with Merck's US chemicals headquarters. In addition, Merck said that it intends to "build on Millipore's talented workforce and intends to retain its senior management."

Merck will fund the acquisition with available cash and a term loan provided by Bank of America Merrill Lynch, BNP Paribas, and Commerzbank Aktiengesellschaft. It plans to replace part of the facility through the issuance of bonds.

The boards of directors of both firms have approved the transaction, which will require the approval of Millipore's shareholders. The firms expect to complete the deal in the second half of 2010.

In a research note issued on Monday morning, Thomas Weisel analyst Peter Lawson said that the Merck-Millipore deal "refocuses attention on the potential of industry consolidation."

In early Monday trade on the New York Stock Exchange, shares of Millipore were up 11 percent at $104.88.

Millipore Exploring Alternatives Following News of Acquisition Bid

Millipore said late last night that its board of directors is evaluating "strategic alternatives to enhance shareholder value," including a potential merger or sale of the company.

Millipore's statement comes two days after Bloomberg reported that Thermo Fisher Scientific had made a $6 billion bid for the firm.

Millipore confirmed that it has hired Goldman Sachs as its financial advisor and Cravath, Swaine & Moore as its legal advisor to assist the board in its evaluation.

Millipore also said that it has not set a timetable for completing the evaluation and cannot assure that it will lead to any transaction.

In early Wednesday trade on the New York Stock Exchange, shares of Millipore were up 3 percent at $91.50. Its shares are up 28 percent for the week.

Unique database of Bioinformatics tools and softwares - from SciClips

Sciclips has recently launched a unique database of bioinformatics
tools and software for reserchers. This database contains links
to more than 2000 web-based bioinformatics and software tools
for DNA, RNA, proteins, genomics, proteomics, drug discovery
research and many more.

This database is the largest online collection for bioinformatics tools
and software that is freely available to the researchers.
This one-stop extensive bioinformatics database will help researchers
in retrieving, analysing the most relevant biological data and
extracting information from them efficiently for genomics,
proteomics and drug discovery and other areas of research.

Bioinformatics Tools and Database Protocols

Transfer of pharmaceutical data resources, private to public domain has greatest impact

While this is very encouraging what's going to be it's impact on the industry on proprietary database vendors? More & more of open database consortia and open curation models are on the offing, with high level of participation from both the academia and the Industry.

The European Molecular Biology Laboratory's European Bioinformatics Institute has launched a "vast online database" of genomic-based drug and small molecule information available in an open access format for researchers seeking new therapeutics, according to EMBL-EBI.

The ChEMBLdb holds translational information on more than 520,000 small molecules, including data on target binding, the affect these compounds have on cells and organisms, and information about the molecules' absorption, distribution, metabolism, excretion, and toxicity.

"The data lie at the heart of translating information from the human genome into successful new drugs in the clinic," EMBL-EBI said this week.

EMBL-EBI is hosting the database, which was transferred from the biotech company Galapagos through a £4.7 million ($7.7 million) Strategic Award from the Wellcome Trust.

"This unprecedented transfer of pharmaceutical data resources from the private sector to the public domain should have the greatest impact on researchers in academia and in small companies on limited budgets," Alan Schafer, director of science funding at the Wellcome Trust, said in a statement.

"ChEMBLdb will be a major resource of information for driving forward medicinal chemistry and drug development in the UK and internationally," Schafer said.

EMBL-EBI also said that, along with partner Wellcome Trust, it has released an integrated resource of sequence, compound, and screening data from a range of sources for protein kinases, called Kinase SARfari.

Several positions open at Polyclone, Biobase, ocimumbio...

Several position

http://www3.ocimumbio.com/about/careers/

http://www.mgrc.com.my/careers.shtml

http://www.biobase-international.com/index.php?id=400

http://www.polyclonebio.com/opportunities.html

http://www.genedata.com/company/careers/ch-gdp-2006.html

http://www.biomatters.com/default,24,careers.sm

http://www.atgclabs.com/Jobs.html

http://www.clcbio.com/index.php?id=12

XTractor Premium - A Platform for discovery, knowledge sharing, analysis and modelling of published biomedical facts.

• The only Knowledgebase which provides "manually" annotated facts from PubMed on a weekly basis
  
• Innovative Features like Semantic Search, Concept Linking, Bibliographic search, Save, Export and Visualize
  
• Only Knowledgebase with daily updations from PubMed
  
• XTractor Premium now at an Special Introductory Offer. Subscribe now and save!
  
• Request for a Trial